Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts

Table 1 Associations of progress free interval and clinicopathological characteristics in clinical patients using Cox regression

Characteristics	Total (N)	Univariate analysis		Multivariate analysis
		Hazard ratio (95%CI)	P value	Hazard ratio (95%CI)	P value
Age	271	0.965 (0.921-1.012)	0.140
HBP	271
Yes	141	Reference
No	130	0.905 (0.474-1.729)	0.763
DM	271
Yes	40	Reference
No	231	0.873 (0.364-2.093)	0.761
PSA	271	1.021 (1.008-1.035)	0.002	1.017 (1.000-1.033)	0.045
T stage	271
T3&T4	98	Reference
T1&T2	173	0.349 (0.181-0.673)	0.002	0.824 (0.373-1.819)	0.631
N stage	271
N0	263	Reference
N1	8	10.022 (3.885-25.850)	< 0.001	5.165 (1.756-15.194)	0.003
M stage	271
M0	270	Reference
M1	1	73.441 (8.365-644.773)	< 0.001	0.912 (0.081-10.244)	0.941
Gleason score	271
6&7	202	Reference
8&9&10	69	3.940 (2.063-7.525)	< 0.001	1.024 (0.401-2.615)	0.961
MKI67(%)	271	1.057 (1.044-1.071)	< 0.001	1.056 (1.037-1.074)	< 0.001

CI: Confidence interval; HBP: High blood pressure; DM: Diabetes mellitus; PSA: Prostate-specific antigen; MKI67: Marker Ki-67.